Is BioNTech SE (BNTX) a Promising Biotech Stock According to Wall Street Analysts
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...
Looking At BioNTech's Recent Unusual Options Activity
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...
Deutsche Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BioNTech SE (BNTX) Gets a Buy from Goldman Sachs
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...
Nasdaq3d
Looking At BioNTech's Recent Unusual Options Activity
Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ:BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Fintel on MSN15d
Citigroup Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy Recommendation
Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 41.58% Upside As ...
Analysts Set Expectations for BioNTech FY2024 Earnings
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report issued to clients and investors on Monday, March 10th. HC Wainwright ...